Clinical application of Pazopanib in the treatment of bone and soft tissue sarcoma

Pazopanib (Pazopanib) is an oral multi-target tyrosine kinase inhibitor (TKI) that can inhibit vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR) and c-KIT and other key targets, thus interfering with tumor angiogenesis and cell proliferation. In the treatment of bone and soft tissue sarcoma (STS, Soft Tissue Sarcoma), pazopanib is considered an effective option for advanced or refractory patients due to its anti-angiogenic effect and good oral accessibility. The following is a detailed analysis from the aspects of indications, clinical trial data, efficacy analysis and safety management.

1. Indications and clinical application background

Bone and soft tissue sarcoma is a heterogeneous and highly aggressive tumor. Traditional chemotherapy (such as doxorubicin, etoposide) has limited efficacy in advanced patients and is accompanied by significant toxicity. As an anti-angiogenesis targeted drug, pazopanib can inhibit the formation and growth of tumor blood vessels by blocking the VEGFR/PDGFR signaling pathway, providing a new treatment option for patients who cannot be surgically resected or are resistant to traditional chemotherapy. In 2012, Pazopanib was approved in Europe and the United States for the second-line and third-line treatment of advanced soft tissue sarcoma, but does not include liposarcoma.

2. Key clinical trials and efficacy evaluation

In the PALETTE trial, patients with advanced soft tissue sarcoma treated with pazopanib showed The median progression-free survival (PFS) was 4.6 months, which was significantly longer than the 1.6 months of placebo, suggesting that pazopanib has an advantage in controlling disease progression. Although overall survival (OS) did not show significant improvement, the disease control rate (DCR) increased to 73%, and the tumor shrinkage ratio is high, showing effective disease stabilization in advanced patients. In addition, some small studies and real-world data also show that pazopanib is more effective in angiosarcoma, fibrosarcoma and undifferentiated soft tissue sarcoma, while patients with liposarcoma do not respond well to the drug.

3. Treatment Strategies and Combination Drug Exploration

In clinical application, pazopanib is often used as a second-line or third-line treatment option, providing a feasible option for patients who have received doxorubicin or ifocisplatin and whose disease has progressed. The standard dose is 800 mg/ taken orally once a day. In case of poor tolerance or adverse reactions, the dose can be adjusted according to blood pressure, liver function and blood picture. In recent years, researchers have also tried to combine pazopanib with immune checkpoint inhibitors (such as PD-1/PD-L1 antibodies) to enhance the anti-tumor immune response and extend progression-free survival. Preliminary data show that combination therapy shows observable efficacy in some refractory patients.

4. Safety and adverse reaction management

The adverse reactions of pazopanib mainly include Hypertension, fatigue, abnormal liver function, diarrhea and hand-foot syndrome. Among them, hypertension and abnormal liver function are the most common indicators that need to be closely monitored. It is clinically recommended to monitor blood pressure, liver enzymes and complete blood count regularly before and during treatment, and to remind patients to pay attention to weight changes, bleeding tendencies and cardiovascular symptoms. In the event of moderate or severe adverse reactions, toxicity can be controlled by dose reduction (600 mg or 400 mg/day), temporary drug discontinuation or symptomatic treatment. With scientific monitoring and management, most patients can continue to complete the treatment cycle and maintain efficacy.

5. Summary

Overall, pazopanib has clear efficacy in the treatment of bone and soft tissue sarcoma The anti-tumor angiogenesis effect can significantly extend progression-free survival, improve disease control rate, and provide an effective second-line treatment option for advanced or refractory patients. Its advantages of oral administration, relatively controllable adverse reactions and the potential to be combined with other targeted drugs or immunotherapy make it one of the important drugs in the management of soft tissue sarcoma in clinical practice. Reasonable dose adjustment, regular monitoring and side effect management are the keys to ensuring efficacy and safety. Through individualized treatment strategies, patients can achieve lasting disease control while maximizing side effects.

Reference link:https://www.drugs.com